Arrowhead Pharma (ARWR): RNAi on DeckARWR’s RNAi tech isn’t getting the hype it deserves yet, but these guys are building something powerful. If trial results hit, this could be a biotech leader. Meanwhile, MYNZ keeps building solid partnerships that fly under the radar—exactly what I like in a long-term setup.